To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.

HR8163 was introduced March 30, 2026, by Rep. Murphy (R-NC) with 18 bipartisan cosponsors and referred to Energy & Commerce and Ways & Means. The bill amends Section 1848(c)(2)(B) of the Social Security Act to raise the budget neutrality threshold from $20M to $54.3M in 2027 and index it to the Medicare Economic Index (MEI) every five years starting 2032. It also mandates CMS to reconcile estimated vs actual utilization when applying budget neutrality adjustments. This is a calculation methodology change—no taxpayer funds are authorized or appropriated. The money trail is indirect: Medicare Advantage plans reimburse providers using rates linked to the Medicare Physician Fee Schedule. When budget neutrality triggers across-the-board fee cuts, MA plans face sudden provider payment reductions that destabilize networks and introduce MLR volatility. This bill reduces the probability of those cuts by raising the trigger threshold and requiring utilization corrections. The Congressional Budget Office would likely score this as negligible direct budget impact since it only changes when cuts occur, not whether they occur. Structural winners are pure-play Medicare Advantage insurers: $HUM (85% MA revenue), $UNH (largest MA operator via UnitedHealthcare, ~$120B MA premiums), and $CVS (Aetna MA + Oak Street capitated primary care). Diversified managed care companies with smaller MA exposure ($CI, $ELV) benefit proportionally less. Hospital systems and physician groups benefit indirectly from reduced reimbursement volatility but face no direct mechanism. Real market data confirms strong recent momentum: $UNH up 3.61% (7-day) to $367.74, $CVS up 6.97% to $83.37, $HUM up 11.84% to $240.71. Over 30 days, $HUM has surged 38.83%, $UNH 35.9%, and $CVS 16.08%. This rally likely reflects expectation of bipartisan support—the bill has 18 cosponsors spanning both parties in an evenly divided House—and the fact that physician payment reform has persistent bipartisan appeal as a 'fix broken Medicare' narrative. Remaining legislative path: Referred to two committees (Energy & Commerce; Ways & Means) with no hearing or markup scheduled. Passage probability is low-moderate for this Congress given early-stage status and crowded health care agenda. However, the narrow procedural scope and bipartisan cosponsorship suggest it could be attached to must-pass year-end health extenders if momentum builds.